Salute e Benessere

Turacoz Group Showcases Expertise in Medical Communication at BioEurope Spring…

During the three-day event, Turacoz Group's representatives Ashish Pandey along with Turacoz founder Dr. Namrata Singh, engaged intensively with industry leaders to highlight Turacoz's unique ability to create Clear, Cohesive, Complete, Concise, and Concrete scientific communication in a target-specific language and format. This expertise is crucial for biopharma companies facing challenges in effectively communicating complex scientific data, especially in areas of rare diseases and strict…
PR Newswire
03/04/2024

Tianlong Participated in International Medical Congress of SCO Countries in…

Tianlong was also invited to join in a series of conferences and exchanges in Kyrgyzstan. At an international conference on "Topical issues of laboratory medicine", Jessica Wu(PhD of Molecular Biology) from Tianlong's Overseas Marketing Dept, delivered a speech about "LigSeq Reagent Kit - Tianlong's personalized medication solutions". During the presentation, Dr. Wu discussed the significance of personalized medication and shared the latest research and application cases. She…
PR Newswire
03/04/2024

Value innovations address health concerns amid rising costs

Taken from Nutiani's latest report, Health, Nutrition and Rising Costs, which was launched today, these insights were derived from a refreshed Consumer Health and Nutrition Index that was conducted in collaboration with Ipsos. The research surveys 2,500 respondents across China, Japan, South Korea, the United Kingdom and the United States. Taken from Nutiani's latest report,Health, Nutrition and Rising Costs, which was launched today, these insights were derived from a refreshed Consumer...
PR Newswire
03/04/2024

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic…

CHICAGO & PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics. CHICAGO&PALO ALTO, Calif.,April 3, 2024/PRNewswire/ -- SimBioSys, a…
PR Newswire
03/04/2024

Human Frontier Science Program: Research Grants Awarded to 108 of the Most…

Scientists working in these nations have won HFSP Research Grants for 2024-2027: Scientists working in these nations have won HFSP Research Grants for 2024-2027: Online Booklet Listing Winners, Laboratories, Institutions, and Planned Work: To view the2024 HFSP ResearchGrant Awardees and theIndex by Country of the ResearchGrant Awardees . About HFSP Awards: HFSP Research Grants last for three years and on average, provide$400,000 USDper year. OurProgram...
PR Newswire
03/04/2024

Latvian pharmaceutical manufacturing company Grindeks opens new subsidiaries…

To expand its export markets, Grindeks has established 28 subsidiaries in Europe and other countries around the world, including Canada and the United States. Already in 2022, Grindeks began diversifying its export markets by opening 28 subsidiaries in various countries, gradually commencing operations. Last year, operations were initiated in established companies in Poland, the Netherlands, Portugal, Romania, the United Kingdom, Belgium, Germany, Finland, Slovakia, the Czech Republic, Norway…
PR Newswire
03/04/2024

Pharming Group to participate in April investor conferences

Leiden, The Netherlands, April 3, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of April: 23rd Annual Needham Virtual Healthcare Conference, April 8-11, 2024Sijmen de Vries, Chief Executive Officer, will present on Monday, April 8 at 8:45ET/14:45CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News”...
Nasdaq GlobeNewswire
03/04/2024

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of…

Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumorsGenmab to host...
Nasdaq GlobeNewswire
03/04/2024

Strong data from DSR® proof-of-concept studies in heart failure published in…

Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance Ghent, Belgium – 3 April 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the results from two proof-of-concept studies, RED DESERT and SAHARA, of the Company's DSR therapy in patients with diuretic-resistant heart failure have been published…
Nasdaq GlobeNewswire
03/04/2024

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain…

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGENEVA, Switzerland – April 3, 2024– ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH1260041939) from SIX Swiss Exchange and has exempted the company from certain obligations associated with...
Nasdaq GlobeNewswire
03/04/2024

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate…

Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland and New York, USA, April 3, 2024 -Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric...
Nasdaq GlobeNewswire
03/04/2024

Contraceptive Market Projected to Reach $119.89 billion by 2030 - Exclusive…

Family planning is crucial for health and well-being, and contraceptives serve as essential tools that empower individuals to decide if and when to have children. These methods vary in function, preventing pregnancy by either blocking fertilization, hindering the implantation of fertilized eggs, or controlling hormonal cycles. Recent years have witnessed a rise in the adoption of contraception, fueled by educational initiatives and enhanced access to healthcare across the globe, especially in…
PR Newswire
03/04/2024

Retinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 |…

Key Takeaways from the Retinitis Pigmentosa Market Report Key Takeaways from the Retinitis Pigmentosa Market Report Discover which therapies are expected to grab the major retinitis pigmentosa market share @Retinitis Pigmentosa Market Report Retinitis Pigmentosa Overview Retinitis pigmentosa denotes a collection of hereditary retinal disorders that result in the degeneration of the retina and eventual blindness. The condition is marked by the gradual deterioration of both...
PR Newswire
02/04/2024

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3…

Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapyConfirmation of injection feasibility and favorable safety profile in completed Phase 1 dose escalation part of the study support potential for later stage development of NBTXR3 for the treatment of patients with inoperable, recurrent NSCLC who are amenable to re-irradiationThe dose expansion...
Nasdaq GlobeNewswire
02/04/2024

Explosive Growth Projected in US Pet Medication Market, the Industry to Reach…

The U.S. Pet Medication Market Report Scope The U.S. Pet Medication Market Report Scope The US pet medication market is projected to increase, driven by the pet humanization trend and the ensuing commercialization of a broad range of pet care products coupled with the growing focus on safe food and a parallel emphasis shed on raising healthy livestock. The rising throwaway income of pet owners pertains to the middle-income group, and the growing trend of nuclear families is the...
PR Newswire
02/04/2024

E-commerce Boom and Eco-Friendly Trends Shape the U.S. Lawn and Garden…

The U.S. Lawn and Garden Consumables Market Report Scope The U.S. Lawn and Garden Consumables Market Report Scope In the US lawn and garden consumables market, the rising demand for organic and sustainable products is a prominent trend. Consumers increasingly opt for environmentally friendly options, prompting market players to diversify their product ranges with eco-conscious offerings. Technological integration is also reshaping gardening practices, with smart gardening...
PR Newswire
02/04/2024

Robust and Portable Baby Scales Reshape Medical & Physician Scale Industry, the…

Browse In-depth TOC on the Medical & Physician Scale Market Browse In-depth TOC on the Medical & Physician Scale Market 287 – Pages 101 - Tables 85 - Figures The Global Medical & Physician Scale Market Report Scope The introduction of essential features in baby scales tailored for the professional medical sector has had a significant impact on the medical scale market. With Class III approval ensuring reliability and...
PR Newswire
02/04/2024

Crossject trading on Euronext to resume as usual on Wednesday April 3

Dijon, France April 2, 2024 –Trading of the stock ofCrossject (ISIN: FR0011716265; Euronext: ALCJ)on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET.Crossject's press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations.For that reason, Crossject required Euronext to stop trading. Following Euronext's standard procedure in such...
Nasdaq GlobeNewswire
02/04/2024

Virbac acquired Sasaeah, a leading animal health player in Japan

On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.Formed through the combination of two legacy animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the stewardship of ORIX Corporation, Sasaeah generates annual revenues...
Nasdaq GlobeNewswire
02/04/2024

Number of voting rights as of March 31, 2024

Nicox SA Société anonyme with a registered capital of € 50,299,694 Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot R.C.S. ANTIBES 403.942.642 On April 2 nd, 2024, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l'AMF) As of March 31, 2024Total number of...
Nasdaq GlobeNewswire
02/04/2024

Nurse Call Systems Market Worth $4.0 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=230909048 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=230909048 Browse in-depth TOC on "Nurse Call Systems Market" 374 - Tables 42 - Figures 302 - Pages Nurse Call Systems Market Scope: In 2023, the button-based systems segment held the largest share of the nurse call systems market by type segment. Based on type, the nurse...
PR Newswire
02/04/2024

eXeX & AdventHealth Surgery Center Innovation Tower Pioneer Use of Apple Vision…

AdventHealth Surgery Center Innovation Tower and eXeX partnered in 2023 to introduce spatial computing and artificial intelligence technology to the hospital's surgical teams. eXeX's software offers technicians holographic and touch-free access to the surgical setup, inventory, and procedural guides from within the sterile field of the operating room, granting them access to data and visualization that was previously never available. The platform has significantly increased efficiency of…
PR Newswire
02/04/2024

Benevolent AI's largest shareholder seeks governance shake-up in the company he…

Dr. François Nader Chairman BenevolentAI S.A. 9, rue de Bitbourg L - 1273 Luxembourg Dr. François NaderChairmanBenevolentAI S.A.9, rue de BitbourgL - 1273 Luxembourg (By email) 28 March 2024 Dear François, NOTIFICATION OF SHAREHOLDER INTENTION As the Founder and largest shareholder of BenevolentAI, (the "Company") I have been in regular formal correspondence with the Board over a long period of time to raise issues that I believe have significantly constrained the...
PR Newswire
02/04/2024

KFSH&RC Welcomes Dr. Björn Zoéga as New Deputy CEO

RIYADH, Saudi Arabia, April02, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024. This strategic move is set to accelerate KFSH&RC's aspiration of becoming a leading healthcare institution on the global stage, leveraging Dr. Zoéga's notable career and proven track record of leadership in top-tier medical institutions...
Nasdaq GlobeNewswire
02/04/2024
Altri  Comunicati